Navigation Links
David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
Date:8/4/2008

DURHAM, N.C., Aug. 4 /PRNewswire/ -- Regado Biosciences today announced the appointment of David J. Mazzo, Ph.D., as President and Chief Executive Officer (CEO), effective immediately. Dr. Mazzo brings to Regado almost 25 years of experience in the pharmaceutical industry, most recently as President and CEO of AEterna Zentaris. Dr. Mazzo also has served as President and CEO of Chugai Pharma USA, LLC, the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan, a member of the Roche Group. Dr. Mazzo replaces Regado co- founder Douglas Gooding.

Dennis Podlesak, Chairman of the Board of Regado, stated, "Dr. Mazzo's appointment comes at an important growth phase for the Company. The data from our ongoing Phase IIa study of the REG1 Anticoagulation System are expected later this year. This is the first study of the REG1 system in patients undergoing percutaneous coronary intervention. Dr. Mazzo's senior leadership experience, his strong scientific background and commercial and regulatory expertise will be invaluable to the Company as Regado advances and expands its clinical development programs."

Throughout his career in the pharmaceutical industry, Dr. Mazzo has acquired a thorough understanding of the drug development process from discovery through manufacturing, launch and commercialization. Prior to joining Chugai, Dr. Mazzo held positions of increasing responsibility with Merck & Co., Baxter, Rhone-Poulenc Rorer, Hoechst Marion Roussel, and Schering-Plough.

Dr. Mazzo commented, "I am excited for the opportunity to lead Regado through its next stage of growth. My primary goals are to build upon the Company's established success and further harness the great potential in Regado's lead programs and discovery platform. The Company is unique in its focus on developing aptamer therapeutics paired with agents that can directly modulate their activity. This has the potential to provide unprecedented control to the physician and represents an
'/>"/>

SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. NSF International Acquires David Begg Associates
2. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
3. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
4. David Barker, Former Illumina CSO, Joins GenVaults Scientific Advisory Board
5. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
6. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
7. Immunosyn Corporation Names G. David Criner as CFO
8. Pasteuria Bioscience Taps New CEO David N. Duncan
9. David Mott Appointed Non Executive Director at Shire
10. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
11. Transgenomic Appoints David Pauluzzi to Board of Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...,, SCHIEDLBERG, Austria, November 9 /PRNews...er the world have been working on the development ...ect communication channel,between the brain and a ...ed,patients to communicate or to control devices i...g the last years some patients have been supervise...
(Date:11/9/2009)... Product release is a res... subjects, research facilities and research safety...ion. , Cedar Knolls, NJ (...announced today that it has unveiled Pristima&trad...for research facilities that track the use and car...
(Date:11/6/2009)...,, TORONTO, Nov. 6 /PRNewswire-FirstCall/ - Mic...day that it has re-filed the Form 52-109F1 Certifi...ief Executive Officer and James Long, the Chief Fi...ed January 12, 2009 in connection with the annual ...ptember 30, 2008. ,, The Company initially file...
(Date:11/6/2009)...,, SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstC..., Completed transfer of Qutenza(TM) E.U. Marketin...ade significant progress in commercial readiness a...Sales; Senior Director, Marketing; and Director, C...n to board as director and Audit Committee chairma...
Breaking Biology Technology:intendiX - Communication by Thoughts: First Patient-Ready System on the Market 2Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management 2NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10
... , When: Tuesday, April 22 ... Networking Reception 5:30 p....30 p.m., Where: 610 Hilton Blvd., A...courtaa.com/ann_arbor_city_map_directions.html ), ...ranslation Industry experts ...
...ewswire-FirstCall/ - Victhom Human Bionics,Inc. (V...from the ongoing,human clinical trial of its Close...urostep(TM) for the treatment of patients sufferin...stem lesion. According to the Company, the,initial...eurostep(TM) is,capable of collecting sensory sign...
... 16 /PRNewswire-FirstCall/ - Anavex Life,Sciences ... appointment of,Dr. Dimitri Goundis as Project Dir...res to enter human clinical trials with its lead A...r. Goundis has more than 20 years experience in th...hip positions at Speedel AG (SWX: SPPN),The Medici...
Other Biology Technology:MichBio Will Host Workshop on Capital Formation Prior to April 22 Annual Meeting 2Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system 2Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 2Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 3Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 4
(Date:11/5/2009)...rsity have developed synthetic molecules capable o...HIV-infected cells, as well as to prostate cancer ...urnal of the American Chemical Society , could lea...es. , The molecules called "antibody-recruitin...cruiting molecule targeting prostate cancer" (ARM-...
(Date:11/4/2009)...Long Beach and Riverside are responsible for a sig...a, and the true impact of air pollution and ship e...ated, according to researchers at the University o... appears in an online edition of the American Jou...t of all childhood asthma cases in Long Beach and ...
(Date:11/4/2009)...received more than $10 million in research grants ...stimulus program, bringing thetotal amount of stim...lion. Thirty-three projects achieved stimulus fun...er. , "The university has thoughtfully undertake...rly excellence to federal agency priorities. Thro...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2USC study finds big air pollution impacts on local communities 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 1Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 2Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 3Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 4Cadient Group Brings Home the Gold and Two Bronze Aster Awards 12521 1Cadient Group Brings Home the Gold and Two Bronze Aster Awards 12521 2RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 1RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 2RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 3RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 4RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 5RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 6
...ts or animals) that we consume on a daily basis ca... as pesticides or antibiotics. A doctoral thesis c... Department of Analytical Chemistry Department of...da (Universidad de Granada) University of Granada...aa and Laura G miz Gracia, proposes new analysis m...
...published in a prestigious American science journa...nd up in fish in as little as three years. Biologi...nada, played a key role in designing and carrying ... mercury emissions from coal-fired power plants an...iately, the amount showing up in fish would begin ...
... cancer tumors from Caucasian and African-American... aggressive in black men. Lead investigator Akhour...d development and research scientist at the Minnea...k mens tumors are more aggressive is based on stud...d only indirect means to measure tumor aggressiven...
Other Biology News:Alternative methods proposed to detect pesticides and antibiotics in water and natural food 2University of Minnesota study refutes belief that black men have more aggressive prostate cancer 2University of Minnesota study refutes belief that black men have more aggressive prostate cancer 3
BD BaculoGoldTM Transfection Kit 5 transfections from BD Biosciences Pharmingen
Sf9 Insect Cells from BD Biosciences Pharmingen
UltraClean Plant DNA Isolation Kit from Mo Bio Laboratories, Inc.
Propidium iodide from Research Organics, Inc.
Biology Products: